Hanson Wade Group have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or disappointment this will cause.

Please register your interest here if you would like updates on the meeting or topic

Achieve Clinical Proof of Concept Through Precision Targeting of the Tumor Microenvironment With Improved Translation, Biomarkers & Safety Profiles

Welcome to the 4th Annual Tumor Myeloid Targeting Therapies Summit

Targeting Macrophages, Neutrophils, Dendritic Cells and MDSCs

Myeloid cell-based therapies have proven to be promising therapeutic strategies for cancer. With the field ever evolving and progressing into the clinic, the upcoming 4th iteration of theTumor Myeloid Targeting Therapies Summit is poised to bring together innate immunity experts from across the biopharmaceutical industry and academic landscape.  

We have collaborated with the most influential thought leaders fromMD Anderson, Gilead Sciences, Onchilles Pharma, DEM Biopharma, NGM Biopharmaand many more to uncover translational lessons learned in liquid and solid tumor indications. 

With a primary focus on the diversity of myeloid cells, exploration and discovery of novel targets and biomarkers and intricate interactions within the TME, this dedicated meeting strives to accelerate your promising discoveries from bench to bedside. 


World-Class Speaker Faculty Includes:

Previously Attending Companies Include:

Copy of Company logo slider

What Our Past Attendees Had To Say:

“ The small intimate setting was conducive for open and deep discussions as well as sharing of data and insights
Gilead Sciences

“ Going to a niche conference like this with the leaders in tumor myeloid therapy was a great learning experience for me and was also a great networking opportunity
Carisma Tx

Our Partners:


Other Events in the Series: